Azomid

Quick links to important sections

Azomid

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azomid

Quick Facts

Property Description
Active Ingredient Acetazolamide
Form Tablet, Extended-release Capsule, Powder for Injection
Pharmacological Class Carbonic Anhydrase Inhibitor
Common Use Fluid and Pressure Regulation
Origin Synthetic Sulfonamide Derivative

Azomid: A Specialized Carbonic Anhydrase Inhibitor

Azomid is a commercial brand name for the prescription drug Acetazolamide, which is primarily classified as a first-generation carbonic anhydrase inhibitor. This compound is a chemically synthetic sulfonamide derivative, although it is non-antibiotic and non-bacteriostatic. The medication’s classification is clinically recognized, reflecting its established role in therapeutics. Azomid, like other Acetazolamide formulations, is positioned for use across adults and certain pediatric patient groups under medical guidance.

Composition and General Purpose

Azomid is a single-ingredient product, containing only Acetazolamide as the active substance. It is supplied in various dosage forms, including oral tablets and extended-release capsules designed to offer a different pharmacokinetic profile, as well as a sterile powder for injection for intravenous use. The overall general purpose of Azomid is to influence systemic fluid regulation and achieve the reduction of fluid pressure within specific closed compartments of the body. Its unique action on the carbonic anhydrase enzyme impacts fluid secretion across multiple tissues. Consequently, the medicine is generally utilized in scenarios requiring a regulated influence over internal pressure environments, such as those related to excessive fluid accumulation or pressure imbalances.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Azomid?

Possible Side Effects and Safety Information

Azomid (Acetazolamide) is a sulfonamide derivative whose officially documented safety profile includes a range of adverse reactions classified by frequency and system involvement, as documented by regulatory authorities.

Frequency-Classified Adverse Reactions

The most frequently reported effects relate primarily to changes in fluid balance and sensation:

  • Very Common: These include paresthesia (a tingling sensation, often in the extremities), polyuria (increased urination), and taste disturbance (dysgeusia).
  • Common: Effects such as anorexia, nausea, vomiting, diarrhea, headache, dizziness, and fatigue are classified in this category.
  • Rare: Documented rare reactions include renal calculus (kidney stones) and severe blood dyscrasias (e.g., aplastic anemia, agranulocytosis). Certain severe reactions like Stevens-Johnson Syndrome and fulminant hepatic necrosis have been reported with a frequency of Not Known.

System-Organ Class and Time-Related Patterns

The effects are grouped into system classes, notably Metabolism and Nutrition Disorders (e.g., metabolic acidosis, electrolyte imbalance) and Renal and Urinary Disorders (e.g., nephrolithiasis). Paresthesia is often reported to be more noticeable at the start of treatment. Conversely, the risk of developing renal stone formation and persistent metabolic acidosis is associated with long-term exposure.

Safety Restrictions and Serious Adverse Reactions

Official labeling mandates that the medicine is contraindicated in patients with severe hepatic impairment (e.g., cirrhosis), severe renal impairment, or known sulfonamide hypersensitivity. Caution is also warranted for use in older adults. The official profile includes rare but serious events such as severe blood disorders and severe cutaneous reactions, underscoring the importance of adhering to the prescribed safety limits.

Overdose and Emergency Response

Official regulatory information for Azomid indicates that no cases of acute poisoning in humans have been reported, and no specific antidote is known. Consequently, the official management approach is defined as strictly symptomatic and supportive treatment. Overdosage is expected to lead to a significant electrolyte imbalance, resulting in conditions such as hypokalemia (low potassium), and the development of an acidotic state (metabolic acidosis).

Immediate medical attention must be sought if overdosage is suspected or if signs of severe toxicity are observed. The label also requires specific action for severe outcomes, including life-threatening sulfonamide-related reactions. A specific severe toxicity syndrome, marked by metabolic acidosis, coma, and death, has been reported when Azomid is used concurrently with high-dose aspirin (salicylates).

Mandatory supportive measures include continuous monitoring of serum electrolyte levels and blood pH levels. This is necessary to guide procedures for the restoration of electrolyte and pH balance. The drug is considered dialyzable, and dialysis may be beneficial in managing overdosage complicated by renal failure.

Therapeutic Uses of Azomid

What Azomid treats: main uses and benefits

Azomid, which contains the active substance acetazolamide, is a medication primarily classified as a carbonic anhydrase inhibitor. It works by interfering with the action of an enzyme in the body, leading to various physiological effects used in the management of specific medical conditions.

Management of Glaucoma

One of the primary uses of Azomid is the treatment of glaucoma, a condition characterized by increased pressure within the eye. The medication helps reduce intraocular pressure by decreasing the production of aqueous humor, the fluid found in the front part of the eye. It is utilized in various forms of the condition, including:

  • Chronic simple (open-angle) glaucoma: Used as an adjunctive treatment when standard topical therapies are insufficient.
  • Secondary glaucoma: Employed when pressure increases due to other ocular conditions or injuries.
  • Acute congestive (angle-closure) glaucoma: Used as part of short-term preoperative management to lower pressure rapidly before surgical intervention.

Treatment of Edema

Azomid is used as a diuretic to treat edema, which is the abnormal accumulation of fluid in body tissues. Its role in fluid management is typically focused on specific scenarios:

  • Congestive heart failure: It helps the kidneys eliminate excess salt and water, reducing the workload on the heart and decreasing swelling.
  • Drug-induced edema: It may be used to counteract fluid retention caused by certain other medications.

Altitude Sickness Prevention and Relief

The medication is frequently used by individuals ascending to high altitudes to prevent or mitigate the symptoms of acute mountain sickness. It works by accelerating the body's acclimatization process. By increasing the excretion of bicarbonate in the urine, it creates a mild metabolic acidosis, which stimulates breathing and improves oxygenation in environments with lower oxygen levels.

Adjunctive Therapy for Epilepsy

Azomid is sometimes used as an additional treatment for certain types of epilepsy, particularly in cases that do not respond fully to other anticonvulsant medications. It is most commonly associated with the management of:

  • Petit mal (absence) seizures
  • Grand mal (tonic-clonic) seizures
  • Mixed seizure patterns

Its effectiveness in epilepsy is believed to be related to the inhibition of carbonic anhydrase in the central nervous system, which may help stabilize electrical activity in the brain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Azomid?

Eligibility for Azomid (Acetazolamide) is strictly defined by regulatory documents, focusing on patient status, organ function, and pre-existing conditions.

Contraindicated Populations

The medicine is contraindicated and must not be used in specific groups due to formal regulatory prohibition, including:

  • Patients with known hypersensitivity to Acetazolamide or any sulfonamide derivatives.
  • Individuals with marked kidney or liver dysfunction, including liver cirrhosis, due to the risk of hepatic encephalopathy.
  • The presence of metabolic acidosis or depressed blood levels of sodium or potassium (Hyponatremia and Hypokalemia).
  • Patients with Suprarenal Gland Failure.
  • Long-term administration is contraindicated in patients with chronic non-congestive angle-closure glaucoma.

Age and Condition Restrictions

Age Group / Condition Official Regulatory Status
Pediatric Patients Safety and effectiveness have not been established for the conventional tablet and parenteral forms.
Geriatric Patients Caution is advised due to increased likelihood of reduced renal function and risk of metabolic acidosis.
Pregnancy Not recommended during the first trimester; use is only if the potential benefit justifies the risk (Category C).
Lactation Caution should be exercised as the drug is excreted in human milk, potentially requiring discontinuation of nursing or the drug.

Eligibility is also restricted for patients with conditions such as impaired alveolar ventilation or those receiving concomitant high-dose aspirin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Azomid (Acetazolamide) is defined by its effects on drug clearance and systemic additive risks, according to regulatory documents.


Official High-Risk and Restricted Combinations

Co-administration with high-dose Aspirin (Acetylsalicylic acid) is strongly restricted due to documented reports of severe toxicity, metabolic acidosis, and central nervous system effects. The combination with Methenamine is documented to prevent the urinary antiseptic effect of Methenamine. Concomitant use with other Carbonic Anhydrase Inhibitors is not advised due to the risk of additive pharmacodynamic effects.

Pharmacokinetic and Clearance Alterations

Azomid is officially documented to influence the plasma concentrations of several co-administered medicines. It may increase blood levels of Phenytoin by modifying its metabolism, and it may elevate Cyclosporine blood levels. By altering urinary pH, Azomid reduces the excretion of basic drugs like Amphetamine and Quinidine, potentially enhancing their effects. Conversely, it increases the excretion of Lithium, leading to reduced blood levels.

Additive Pharmacodynamic Risks

Combining Azomid with Sodium Bicarbonate enhances the official risk of renal calculus formation (kidney stones). There is a possibility of potentiation of effects when used with Oral Anticoagulants and Folic Acid Antagonists. Specific cautions are also noted for elderly patients due to increased vulnerability to interaction outcomes, particularly in those with impaired renal function.

Mechanism of Action

How Azomid Works

Azomid acts as a carbonic anhydrase inhibitor to modify fluid, ion, and pH balance across several biological systems. Its mechanism involves disrupting the reversible conversion of carbon dioxide ( CO2) and water ( H2 O) to carbonic acid ( H2 CO3), which in turn affects hydrogen ion ( H^+) and bicarbonate ( HCO3^-) concentrations.


Regulation of Systemic pH and Ion Balance

This domain covers the inhibition of carbonic anhydrase, primarily in the renal proximal tubules. This action blocks the reabsorption of bicarbonate ( HCO3^-) and sodium ( Na^+), leading to their increased excretion in urine, along with water. The resulting physiological consequence is a mild metabolic acidosis and a diuretic effect, which influences the distribution and elimination kinetics of fluid and ions.


Modulation of Fluid Secretion

This mechanism focuses on the inhibition of the enzyme in specialized tissues like the ciliary processes of the eye and the choroid plexus of the brain. Suppressing the enzyme in these locations reduces the formation rate of aqueous humor and cerebrospinal fluid (CSF). The physiological effect involves reduced formation rates of these fluids, which affects local pressure dynamics.


Neuronal Excitability

Azomid influences carbonic anhydrase found in CNS neurons and glial cells. The local enzyme inhibition alters the delicate pH and ionic gradient surrounding the neurons, resulting in an alteration of neuronal membrane excitability and discharge frequency.

Dosage and Administration Information

How to Use Azomid: Administration Guidelines

Azomid (Acetazolamide) is administered in regimens that vary based on the dosage form and the condition being addressed. The medication is available as immediate-release tablets (125 mg, 250 mg) and extended-release capsules (500 mg) for oral use, and as a 500 mg sterile powder for intravenous (IV) administration.


Dosing and Frequency Patterns

The established dosage range for open-angle glaucoma generally starts from 250 mg to 1,000 mg per day, with amounts exceeding 250 mg typically requiring divided doses. For edema (fluid retention), the dose is often 250 mg to 375 mg, administered once daily in the morning, commonly utilizing a cyclic regimen (e.g., two days on, one day off) to maintain a consistent effect. In managing Acute Mountain Sickness, the administration begins 24 to 48 hours prior to ascent and continues for at least 48 hours while at high altitude.


Administration Requirements

Procedural Instruction Requirement
Timing Relative to Food May be taken with or without food; taking with food is recommended if gastric upset occurs.
Extended-Release Forms Capsules must be swallowed whole and should not be crushed, opened, or chewed.
IV Preparation The powder must be reconstituted with a minimum of 5 mL of Sterile Water for Injection immediately before use.

Population-Specific Use

Specific populations may require adjusted regimens. Pediatric dosing for conditions like glaucoma is calculated on a weight-based scale (e.g., 10 to 30 mg/kg/day, divided). For individuals with renal impairment, dose adjustments are necessary, often requiring the dose to be administered no more frequently than every 12 hours to account for reduced clearance. If a dose is missed, it should be taken as soon as remembered, but not doubled if it is near the time of the next scheduled dose.

Recent Clinical Evidence

Azomid: Recent Clinical Evidence

Clinical research explores the effects of Azomid (acetazolamide) in conditions such as glaucoma, edema (fluid retention), and altitude illness. The agent is a carbonic anhydrase inhibitor, a mechanism that affects fluid and electrolyte balance in the body, which is the focus of therapeutic study.


Core Efficacy Studies

Randomized controlled trials (RCTs) have evaluated whether Azomid might affect intraocular pressure in patients with glaucoma, often showing a reduction in this pressure. Other studies have investigated its use for diuresis (increased urine production) in managing fluid retention. For the prevention of acute mountain sickness, meta-analyses have compared various doses to placebo, with findings suggesting that the lowest investigated dose was associated with a reduced incidence of symptoms.


Long-Term Tolerability and Safety

Long-term research has investigated how the agent is tolerated by patients over several months in chronic conditions, such as idiopathic intracranial hypertension. While most patients can tolerate the medication, especially at lower doses, close monitoring is essential. Studies consistently report that common adverse effects may include paresthesia (tingling), taste disturbances, and fatigue. Less common, but more serious, potential complications include the risk of metabolic acidosis and kidney stones, underscoring the need for individualized risk assessment and ongoing laboratory monitoring during extended therapy.


Research on Dosage and Administration

Studies have explored the pharmacokinetics (what the body does to the drug), showing that Azomid is generally well absorbed after oral administration. Research has also investigated dose ranges across different indications, with findings suggesting that absorption may be dose-dependent. Certain administration findings, such as the relationship between taking the medication with fluids and managing gastric upset, are subject to clinical investigation.

Key Studies & References

  1. Acetazolamide: Drug information (Common Side Effects and Metabolic Acidosis Risk)

Frequently Asked Questions (FAQ)

Common questions about Azomid (FAQ)


Q: Is it possible for Azomid to interact with alcohol?

A: Official information indicates that alcohol use is generally limited while taking Azomid. This is because combining the two may increase the potential for side effects such as feeling dizzy or experiencing drowsiness.


Q: Are there any foods or drinks that should be avoided when using Azomid?

A: While there are no specific foods explicitly restricted in official labeling, alcohol consumption is generally limited. Since Azomid can affect the balance of minerals in the body, such as potentially reducing potassium levels, the need for dietary monitoring or adjustment is a consideration for discussion with a healthcare provider.


Q: How long does it usually take to notice Azomid working?

A: According to official product information, the onset of action for the immediate-release oral form typically occurs within one to four hours after administration. The peak effect of the medication is generally reached within two to four hours.


Q: Is Azomid considered a long-term treatment?

A: Azomid is prescribed for both short-term use, such as for acute mountain sickness, and for long-term management of chronic conditions, including certain types of glaucoma. It is important to know that official documentation notes that long-term use is not advised for patients with chronic non-congestive angle-closure glaucoma.


Q: What are the possible long-term safety concerns with Azomid?

A: Official regulatory documents highlight potential long-term safety concerns associated with the medicine. These include the documented risk of developing metabolic acidosis (a change in the body's acid-base balance) and the formation of renal calculus, which are also known as kidney stones.


Q: What happens if a person misses a dose of Azomid?

A: If a dose is forgotten, official patient information advises taking it as soon as it is remembered. However, you should not double the dose to make up for the missed one if it is almost time for your next scheduled dose.


Q: Can Azomid affect the results of certain medical tests?

A: Yes, official labeling indicates that Azomid can interfere with the accuracy of certain laboratory tests. This includes tests used to monitor the levels of serum electrolytes and blood cell counts, which is important because the drug affects the body's fluid and ion balance.


Q: What is the chance of getting a serious side effect from Azomid?

A: The serious adverse effects noted in official documentation, such as severe blood disorders or kidney stones, are generally classified as rare or of not known frequency. This indicates that while possible, these events are considered uncommon or infrequent based on regulatory data.


Q: Is Azomid generally well-tolerated by most patients?

A: Regulatory sources suggest that most patients are able to tolerate the medication, particularly when used at lower amounts. However, it is common to experience side effects like paresthesia (tingling sensation) and fatigue, especially when first starting treatment.


Q: What is the common reason why a healthcare provider might discontinue Azomid?

A: Official labeling identifies several situations that would necessitate stopping the medicine. These include if a patient develops severe contraindications like marked kidney or liver failure, or if certain serious adverse reactions develop, such as severe blood disorders.


Q: Are headaches a common side effect reported with Azomid?

A: Yes, regulatory documents classify headache as a common adverse reaction associated with Azomid use.


Q: What does the evidence say about Azomid's effectiveness?

A: Official therapeutic indications are supported by evidence from clinical trials. These studies have shown that Azomid is effective in reducing intraocular pressure in various forms of glaucoma and in promoting diuresis (increased urine production) to help with fluid retention.


Q: Is Azomid usually started at a low amount?

A: Official prescribing information provides a range of established dosages for different conditions. While the documents do not universally mandate starting at the lowest possible dose, the regimens often describe a defined starting amount that can be adjusted later.


Q: Can Azomid cause stomach issues or digestive problems?

A: Yes, official product information indicates that gastrointestinal side effects are common. This category includes digestive issues such as nausea, vomiting, and diarrhea.


Q: What is the official recommendation regarding the use of machinery while on Azomid?

A: Because Azomid has the potential to cause side effects such as dizziness and drowsiness, official information advises caution. It recommends against operating machinery or driving until a person knows how the drug affects their ability to perform these tasks.


Q: Is Azomid addictive or habit-forming?

A: Azomid is not classified as a controlled substance in official drug labeling. The regulatory documents do not contain formal warnings or statements regarding its potential for addiction or habit-forming behavior.


Q: Do older adults use Azomid differently than younger adults?

A: Official labeling advises caution when Azomid is used by older adults. This is due to the greater likelihood of reduced kidney function in this population, and such caution may involve a healthcare provider considering adjustments to the administration frequency.


Q: Does Azomid affect fertility or reproductive health?

A: According to official regulatory documents, there is no information available on the effects of Azomid on fertility in humans.


Q: Can Azomid be used by children or teenagers?

A: The official labeling states that the safety and effectiveness of the conventional tablet and powder forms have not been established in children. For the extended-release forms, use is generally restricted to patients who are 12 years of age and older.


Q: Does Azomid have an age limit for use?

A: For the conventional forms of the drug, established safety and effectiveness are lacking in children. For extended-release formulations, official guidance generally restricts use to patients who are 12 years of age and older.


Q: Does Azomid need to be used at a specific time of day?

A: For the treatment of certain conditions, such as edema (fluid retention), the dose is often specified to be taken once daily in the morning. This timing is designed to align with the diuretic effects of the medicine.


Q: Can Azomid make my condition worse temporarily?

A: Official warnings note that the medicine should be used with caution in patients who have existing lung conditions. This is because the drug's mechanism of action may precipitate or aggravate metabolic acidosis, which could potentially worsen their underlying condition.


Q: How should a person prepare before starting Azomid?

A: Official labeling indicates that obtaining a baseline CBC (Complete Blood Count) and platelet count is generally advised before therapy begins. It also recommends periodic monitoring of serum electrolytes (minerals in the blood) throughout the course of treatment.

How should Azomid be stored and disposed of?

How to Store and Dispose of Azomid

Azomid (acetazolamide) tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and kept securely in its tightly closed original container. It is mandatory to store Azomid out of the reach of children.

Disposal Requirements

Unused or expired Azomid must be disposed of according to local regulations for pharmaceutical waste. Do not dispose of the medication by flushing it down a toilet or pouring it down a drain unless specifically advised to do so. Disposal options include utilizing a drug take-back program or, if unavailable, mixing the tablets with an undesirable substance, sealing them in a bag, and placing the bag in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azomid found in:

A-Z Index: